Main Article Content
Abstract
Background: Cholestasis is a disturbance in the production or flow of bile that causes excessive accumulation of bile fluid and damage in the liver. Chronic liver damage will lead to liver fibrosis. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitors of metalloprotease-1 (TIMP-1) play a critical role in liver fibrosis formation. Although ursodeoxycholic acid (UDCA) and Allium sativum extracts have long been renowned for improving liver function, their combination in alleviating liver fibrosis through the MMP-9 and TIMP-1 inhibitory pathways has yet to be studied.
Objective: This study was conducted to assess the efficacy of UDCA and Allium sativum extract combination in altering MMP-9 and TIMP-1 levels, which are the main factors in the progression of liver fibrosis.
Methods: We performed an experimental study with a post-test-only control group on 36 Sprague-Dawley rats, which were randomly grouped into healthy, negative, positive, and three treatment groups with UDCA (13.5 mg) and graded doses of Allium sativum extract (3.6 mg; 7.2 mg; and 14.4 mg). Cholestasis induction was done by a choledochal duct ligation, and treatment was given for 14 days. Levels of MMP-9 and TIMP-1 were analyzed after treatment.
Results: Combining UDCA and Allium sativum improved the MMP-9 levels significantly in cholestatic rats, compared to administrating UDCA only (p <0.05). Combining UDCA and Allium sativum increased the TIMP-1 level (p < 0.05). Although the MMP-9 level results were under our existing hypothesis, TIMP-1 results showed surprising results. Matrix metalloproteinase-9 levels were strongly negatively correlated with TIMP-1 levels, with a r-value= 0.981.
Conclusion: Combining Allium sativum and UDCA alleviates liver fibrosis progression through lowering levels of MMP-9 and increasing levels of TIMP-1.
Keywords
Article Details
Copyright (c) 2024 Anindhita Dyah Sekartaji, Sigit Adi Prasetyo, Muflihatul Muniroh

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish in the Jurnal Kedokteran dan Kesehatan Indonesia agree to the following terms:
- Authors retain copyright and grant Jurnal Kedokteran dan Kesehatan Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution Licence that allows others to adapt (remix, transform, and build) upon the work non-commercially with an acknowledgement of the work's authorship and initial publication in Jurnal Kedokteran dan Kesehatan Indonesia.
- Authors are permitted to share (copy and redistribute) the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Jurnal Kedokteran dan Kesehatan Indonesia.